Voyager Acquisition rises as shareholders back VERAXA Biotech merger

Voyager Acquisition

13/03/2026 10:23

** Shares of healthcare-focused blank‑check firm Voyager Acquisition VACH.O rise 8.8% to $11.97 premarket

** Co says shareholders have approved its merger with Swiss biotech firm VERAXA Biotech AG

** VERAXA develops antibody-based medicines, which use lab-made immune proteins to target disease

** VACH says nearly all shareholders, or 99.67%, redeemed shares for cash ahead of the deal

** Trust account will hold about $885,556 after redemptions, co says

** Combined company expected to trade on Nasdaq under ticker VRXA, pending exchange approval

** Shares rose ~6% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))